PharmAust Limited announced a protocol deviation in its MND trial to elevate a Cohort 1 patient to Cohort 2. With the patient being stable, the Principal Investigator has recommended that the patient be elevated to Cohort 2 and the associated increase in MPL dosage. The patient is later expected to be moved to Cohort 4 with the other Cohort 2 patients, subject to Safety Committee approval.